Antioxidants as therapies: can we improve on nature?

被引:118
作者
Murphy, Michael P. [1 ]
机构
[1] MRC, Mitochondrial Biol Unit, Cambridge CB2 0XY, England
基金
英国医学研究理事会;
关键词
Antioxidant; Drug development; Oxidative damage; Pharmacology; Free radicals; MITOCHONDRIA; THIOREDOXIN; SUBSTRATE; MECHANISM; OXIDANTS; EBSELEN;
D O I
10.1016/j.freeradbiomed.2013.04.010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although oxidative damage contributes to many pathologies the use of naturally occurring, small-molecule antioxidants as therapies for these disorders has not been successful. Here I discuss some of the reasons this may be so. Paramount among these are the difficulties in delivering enough of the antioxidant to the intracellular location required to decrease pathological oxidative damage and the challenge of assessing whether the intervention has actually decreased oxidative damage in the patient to a therapeutically useful extent. To develop effective antioxidant therapies the best strategy may be to create new chemical entities designed to detoxify a defined reactive oxygen species-dependent process that underlies a particular pathology, in the same way a conventional drug is designed to modulate a biochemical process, rather than applying antioxidants in an unfocused manner. In developing new antioxidants it will be useful to utilize endogenous processes to activate and recycle the molecules in parallel with the targeting of compounds to cells and organelles in ways that are not limited by the constraints that impair the distribution of endogenous antioxidants. In short, I suggest that the future development of antioxidant therapies should be viewed as an arm of drug development, utilizing focused approaches similar to those of medicinal chemistry and pharmacology, rather than as a branch of nutrition. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:20 / 23
页数:4
相关论文
共 24 条
[21]   What we learnt from randomized clinical trials and cohort studies of antioxidant vitamin? : Focus on vitamin E and cardiovascular disease [J].
Ueda, Shinichiro ;
Yasunari, Kenichi .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (02) :69-72
[22]   Reconciling the chemistry and biology of reactive oxygen species [J].
Winterbourn, Christine C. .
NATURE CHEMICAL BIOLOGY, 2008, 4 (05) :278-286
[23]   A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase [J].
Zhao, R ;
Holmgren, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :39456-39462
[24]   Ebselen: A substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant [J].
Zhao, R ;
Masayasu, H ;
Holmgren, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (13) :8579-8584